SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: software salesperson who wrote (2565)4/25/2008 1:27:31 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 3158
 
Cool, wondered what was driving the sucker.

phase II open label extension data for R788 in
rheumatoid arthritis appear to be improving and
upcoming data in NHL is expected to demonstrate
substantial activity

Whoosh!

(the patients were continuing on mtx and there was no neutropenia in placebo recipients.... I can't say that the toxicities are additive, if that's what you're asking.)

Thanks!

Rick



To: software salesperson who wrote (2565)4/25/2008 1:51:07 PM
From: scaram(o)uche  Respond to of 3158
 
>> a phase I dose ranging study has failed to
identify a maximally tolerated dose (MTD) at doses >1gm/day, with no evidence of anemia, seen with Jak 2 and pan-Jak inhibitors <<

Ah, shucks.



To: software salesperson who wrote (2565)4/25/2008 11:44:57 PM
From: Biomaven  Respond to of 3158
 
Interesting discussion. I'll continue this on the Valuation thread to spare those just interested in munches.

Message 24535436

Peter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News